Cytokinetics EVP Research & Development Fady Ibraham Malik reports sale of 3,500 common shares for $224,035

PUBT · 3d ago
Cytokinetics EVP Research & Development Fady Ibraham Malik reports sale of 3,500 common shares for $224,035
  • Cytokinetics EVP Research and Development Fady Ibraham Malik sold 3,500 common shares at $64.01 on Oct. 20, 2026.
  • Malik exercised non-qualified stock options to acquire 3,500 common shares at $7.8 each the same day.
  • Following the transactions, his direct common stock holdings totaled 153,902 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000100), on October 20, 2026, and is solely responsible for the information contained therein.